Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Rational drug design and synthesis of new ╬▒-Santonin derivatives as potential COX-2 inhibitors.

Coricello A, El-Magboub A, Luna M, Ferrario A, Haworth IS, Gomer CJ, Aiello F, Adams JD.

Bioorg Med Chem Lett. 2018 Apr 1;28(6):993-996. doi: 10.1016/j.bmcl.2018.02.036. Epub 2018 Feb 22.

PMID:
29501395
2.
3.

Pro-apoptotic and anti-inflammatory properties of the green tea constituent epigallocatechin gallate increase photodynamic therapy responsiveness.

Ferrario A, Luna M, Rucker N, Wong S, Gomer CJ.

Lasers Surg Med. 2011 Sep;43(7):644-50. doi: 10.1002/lsm.21081.

4.

Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib.

Ferrario A, Lim S, Xu F, Luna M, Gaffney KJ, Petasis NA, Sch├Ânthal AH, Gomer CJ.

Cancer Lett. 2011 May 1;304(1):33-40. doi: 10.1016/j.canlet.2011.01.023. Epub 2011 Feb 19.

PMID:
21339042
5.
6.

Identification of MAP kinase pathways involved in COX-2 expression following photofrin photodynamic therapy.

Luna M, Ferrario A, Wong S, Gomer CJ.

Methods Mol Biol. 2010;635:47-63. doi: 10.1007/978-1-60761-697-9_4.

PMID:
20552339
7.

Targeting the 90 kDa heat shock protein improves photodynamic therapy.

Ferrario A, Gomer CJ.

Cancer Lett. 2010 Mar 28;289(2):188-94. doi: 10.1016/j.canlet.2009.08.015. Epub 2009 Sep 3.

8.

Cyclooxygenase-2 expression induced by photofrin photodynamic therapy involves the p38 MAPK pathway.

Luna M, Wong S, Ferrario A, Gomer CJ.

Photochem Photobiol. 2008 Mar-Apr;84(2):509-14. doi: 10.1111/j.1751-1097.2007.00299.x. Epub 2008 Feb 11.

PMID:
18282182
9.

Multiple components of photodynamic therapy can phosphorylate Akt.

Bozkulak O, Wong S, Luna M, Ferrario A, Rucker N, Gulsoy M, Gomer CJ.

Photochem Photobiol. 2007 Sep-Oct;83(5):1029-33.

PMID:
17880496
10.
11.

Photodynamic therapy: combined modality approaches targeting the tumor microenvironment.

Gomer CJ, Ferrario A, Luna M, Rucker N, Wong S.

Lasers Surg Med. 2006 Jun;38(5):516-21. Review.

PMID:
16607618
12.

Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model.

Ferrario A, Gomer CJ.

J Environ Pathol Toxicol Oncol. 2006;25(1-2):251-9.

PMID:
16566722
13.
14.

CHOP activation by photodynamic therapy increases treatment induced photosensitization.

Wong S, Luna M, Ferrario A, Gomer CJ.

Lasers Surg Med. 2004;35(5):336-41.

PMID:
15611953
15.

The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model.

Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerck YA, Gomer CJ.

Cancer Res. 2004 Apr 1;64(7):2328-32.

16.

Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.

Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ.

Cancer Res. 2002 Jul 15;62(14):3956-61.

17.

Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter.

Luna MC, Chen X, Wong S, Tsui J, Rucker N, Lee AS, Gomer CJ.

Cancer Res. 2002 Mar 1;62(5):1458-61.

18.

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.

Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP.

Cancer Res. 2001 Aug 15;61(16):6185-93.

19.

Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.

Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ.

Cancer Res. 2000 Aug 1;60(15):4066-9.

20.
21.

Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function.

Fisher AM, Ferrario A, Rucker N, Zhang S, Gomer CJ.

Cancer Res. 1999 Jan 15;59(2):331-5.

22.

Photodynamic therapy.

Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q.

J Natl Cancer Inst. 1998 Jun 17;90(12):889-905. Review.

23.

Differential photosensitivity in wild-type and mutant p53 human colon carcinoma cell lines.

Fisher AM, Rucker N, Wong S, Gomer CJ.

J Photochem Photobiol B. 1998 Feb;42(2):104-7.

PMID:
9540217
24.

Increased photosensitivity in HL60 cells expressing wild-type p53.

Fisher AM, Danenberg K, Banerjee D, Bertino JR, Danenberg P, Gomer CJ.

Photochem Photobiol. 1997 Aug;66(2):265-70.

PMID:
9277147
25.

Identification of genes associated with resistance to photodynamic therapy-mediated oxidative stress.

Gomer CJ, Luna MC, Ferrario A.

Methods Mol Biol. 1997;85:263-76. No abstract available.

PMID:
9276330
26.

Chemotherapy plus local treatment in the management of intraocular retinoblastoma.

Murphree AL, Villablanca JG, Deegan WF 3rd, Sato JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ.

Arch Ophthalmol. 1996 Nov;114(11):1348-56.

PMID:
8906025
27.

Cellular targets and molecular responses associated with photodynamic therapy.

Gomer CJ, Luna M, Ferrario A, Wong S, Fisher AM, Rucker N.

J Clin Laser Med Surg. 1996 Oct;14(5):315-21. Review.

PMID:
9612198
28.

Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins.

Gomer CJ, Ryter SW, Ferrario A, Rucker N, Wong S, Fisher AM.

Cancer Res. 1996 May 15;56(10):2355-60.

30.

Photosensitization with derivatives of chlorin p6.

Kessel D, Woodburn K, Gomer CJ, Jagerovic N, Smith KM.

J Photochem Photobiol B. 1995 Apr;28(1):13-8.

PMID:
7791001
31.

Clinical and preclinical photodynamic therapy.

Fisher AM, Murphree AL, Gomer CJ.

Lasers Surg Med. 1995;17(1):2-31. Review.

PMID:
7564853
32.

Photodynamic therapy mediated induction of early response genes.

Luna MC, Wong S, Gomer CJ.

Cancer Res. 1994 Mar 1;54(5):1374-80.

33.
34.

Adriamycin resistance in Chinese hamster fibroblasts following oxidative stress induced by photodynamic therapy.

Fisher AM, Ferrario A, Gomer CJ.

Photochem Photobiol. 1993 Oct;58(4):581-8.

PMID:
8248335
35.

Establishment of a Chinese hamster ovary cell line that expresses grp78 antisense transcripts and suppresses A23187 induction of both GRP78 and GRP94.

Li LJ, Li X, Ferrario A, Rucker N, Liu ES, Wong S, Gomer CJ, Lee AS.

J Cell Physiol. 1992 Dec;153(3):575-82.

PMID:
1332981
36.
37.

Glucose regulated protein induction and cellular resistance to oxidative stress mediated by porphyrin photosensitization.

Gomer CJ, Ferrario A, Rucker N, Wong S, Lee AS.

Cancer Res. 1991 Dec 15;51(24):6574-9.

38.
40.
41.
42.

Porphyrin photosensitivity in cell lines expressing a heat-resistant phenotype.

Gomer CJ, Rucker N, Wong S.

Cancer Res. 1990 Sep 1;50(17):5365-8.

43.
44.

Systemic toxicity in mice induced by localized porphyrin photodynamic therapy.

Ferrario A, Gomer CJ.

Cancer Res. 1990 Feb 1;50(3):539-43.

45.

Properties and applications of photodynamic therapy.

Gomer CJ, Rucker N, Ferrario A, Wong S.

Radiat Res. 1989 Oct;120(1):1-18. Review.

PMID:
2678224
46.

Tissue concentrations of doxorubicin in animal models with engrafted intraocular tumours.

White L, Chan KK, Barrientos A, Gomer CJ, Murpheree AL, Benedict WF.

In Vivo. 1989 Sep-Oct;3(5):315-7.

PMID:
2519871
47.

Laser-induced hyperthermia of ocular tumors.

Svaasand LO, Gomer CJ, Profio AE.

Appl Opt. 1989 Jun 15;28(12):2280-7. doi: 10.1364/AO.28.002280.

PMID:
20555512
48.

Photodynamic therapy in the treatment of malignancies.

Gomer CJ.

Semin Hematol. 1989 Jan;26(1):27-34. Review. No abstract available.

PMID:
2646722
49.

Differential cell photosensitivity following porphyrin photodynamic therapy.

Gomer CJ, Rucker N, Murphree AL.

Cancer Res. 1988 Aug 15;48(16):4539-42.

50.

Ineffective photodynamic therapy (PDT) in a poorly vascularized xenograft model.

White L, Gomer CJ, Doiron DR, Szirth BC.

Br J Cancer. 1988 May;57(5):455-8.

Supplemental Content

Loading ...
Support Center